Renaissance Technologies (RenTech)'s DAWN Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 1.3 M shares of Day One Biopharmaceuticals, Inc. (DAWN) worth $27.81 M, representing 0.04% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in DAWN, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 652,100 shares. Largest reduction occurred in Q2 2023, reducing 239,936 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Day One Biopharmaceuticals (DAWN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Day One Biopharmaceuticals (DAWN) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -8,100 | Reduce 0.62% | 1.3 M | $21.44 |
| Q4 2025 | +399,608 | Add 44.13% | 1.31 M | $9.32 |
| Q3 2025 | -95,064 | Reduce 9.50% | 905,476 | $7.05 |
| Q2 2025 | +652,100 | Add 187.15% | 1 M | $6.50 |
| Q1 2025 | +104,700 | Add 42.96% | 348,440 | $7.93 |
| Q4 2024 | +148,900 | Add 157.00% | 243,740 | $12.67 |
| Q3 2024 | +22,700 | Add 31.47% | 94,840 | $13.93 |
| Q2 2024 | +72,140 | New Buy | 72,140 | $13.78 |
| Q3 2023 | -139,164 | Sold Out | 0 | $0.00 |
| Q2 2023 | -239,936 | Reduce 63.29% | 139,164 | $0.01 |
| Q1 2023 | +231,674 | Add 157.15% | 379,100 | $0.01 |
| Q4 2022 | +49,526 | Add 50.59% | 147,426 | $0.02 |
| Q3 2022 | -18,730 | Reduce 16.06% | 97,900 | $20.03 |
| Q2 2022 | +116,630 | New Buy | 116,630 | $17.90 |
Renaissance Technologies (RenTech)'s Day One Biopharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Day One Biopharmaceuticals, Inc. (DAWN) in Q2 2022, acquiring 116,630 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Day One Biopharmaceuticals, Inc. (DAWN) for 14 quarters since Q2 2022.
Renaissance Technologies (RenTech)'s largest addition to Day One Biopharmaceuticals, Inc. (DAWN) was in Q2 2025, adding 1,000,540 shares worth $6.5 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 1,296,984 shares of Day One Biopharmaceuticals, Inc. (DAWN), valued at approximately $27.81 M.
As of the Q1 2026 filing, Day One Biopharmaceuticals, Inc. (DAWN) represents approximately 0.04% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Day One Biopharmaceuticals, Inc. (DAWN) was 1,305,084 shares, as reported at the end of Q4 2025.